Comparing the current results to its competitors, Bridgebio Pharma Inc reported Revenue increase in the 2 quarter 2026 by 120.39 % year on year. The sales growth was above Bridgebio Pharma Inc 's competitors' average revenue growth of 7.94 %, achieved in the same quarter.
Bridgebio Pharma Inc , slower than the average decrease reported by the company's competitors of -12.7 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -12.7 %
Bridgebio Pharma Inc 's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by competition among established pharmaceutical and biotechnology companies, as well as academic research institutions developing therapies for similar indications. Key competitive factors include clinical performance, regulatory approval, intellectual property protection, pricing and reimbursement, and commercial execution. ATTRUBY (acoramidis) competes with Vyndaqel and Vyndamax (tafamidis meglumine and tafamidis), marketed by Pfizer, Inc. Infigratinib competes with BioMarin Pharmaceutical Inc.'s Voxzogo® (vosoritide) and other investigational therapies. Companies developing clinical treatments for achondroplasia include Ascendis Pharma A/S (TransCon CNP), Tyra Biosciences Inc. (TYRA-300), and Ribomic (RBM-007). Encaleret may compete with conventional therapies and other investigational agents for ADH1. Competitors identified include Ascendis Pharma A/S, BioMarin Pharmaceutical Inc., Pfizer, Inc., Ribomic, and Tyra Biosciences Inc.
October 28, 2025
: BridgeBio Pharma, Inc. is set to reveal the Phase 3 results of their promising candidate, Encaleret, for treating autosomal dominant hypocalcemia type 1 (ADH1). As the anticipation builds, the pharmaceutical industry is keenly observing the company s financial trajectory, which combines staggering revenue growth with ongoing net losses. Through this article, we explore the potential implications of these results on BridgeBio s market position and future.With genetic diseases often underserved in medical research, BridgeBio Pharma has carved a distinctive niche by focusing on innovative therapies for these conditions. As a pivotal moment approaches, the company is poised to announce topline results from the...
September 22, 2025
In the ever-evolving landscape of biopharmaceuticals targeting genetic diseases, BridgeBio Pharma, Inc. stands out as a company committed to advancing treatment options for conditions associated with transthyretin (TTR) amyloidosis, specifically transthyretin amyloid cardiomyopathy (ATTR-CM). With the impending 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) in Minneapolis, new data from the ATTRibute-CM clinical trial about its lead candidate, acoramidis, is set to garner significant attention. Key Presentations at HFSA 2025BridgeBio will showcase extensive findings from the ATTRibute-CM study, including:- One late-breaking clinical trial oral presentation- One formal oral pres...
November 18, 2024
Breakthrough in Achondroplasia Treatment: BridgeBio s Infigratinib Excels in Phase 2 PROPEL 2 Study While Revenues SurgeBridgeBio Pharma, a prominent figure in the biotechnology arena, has marked a significant milestone with the publication of its Phase 2 PROPEL 2 study results in the New England Journal of Medicine. The investigative study centered around infigratinib, a novel therapeutic designed to treat children with achondroplasia, showed promising outcomes. Concurrently, the company has reported robust financial performance in the second quarter of 2024, outpacing its competitors. Infigratinib: A New Hope for Children with AchondroplasiaAchondroplasia, a common form of dwarfism, affects bone growth an...
October 3, 2024
BridgeBio Pharma, Inc. a biopharmaceutical company headquartered in Palo Alto, California, has announced its plans to present outcomes data from its ongoing open-label extension of the ATTRibute-CM study, which evaluates the efficacy of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). This presentation will take place during the American Heart Association (AHA) Scientific Sessions scheduled for November 16-18, 2024, in Chicago, Illinois.Acoramidis is currently being investigated through a Phase 3 clinical trial aimed at confirming its safety and effectiveness for patients diagnosed with ATTR-CM, a rare and potentially life-threatening condition caused by the accumulation of abnormal amy...
September 30, 2024
BridgeBio s FORTIFY Study: A New Hope for LGMD2I/R9 Patients as Enrollment ConcludesBridgeBio Pharma Inc. recently announced the successful completion of patient enrollment in its FORTIFY Phase 3 registrational study of BBP-418, aimed at treating patients with Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). This milestone is a significant step forward for the biopharmaceutical company, as it works to address a rare and debilitating condition that affects muscle strength and mobility.The FORTIFY trial has exceeded its target enrollment, reflecting the desperate need for effective therapies in the realm of muscular dystrophies, particularly LGMD2I/R9, which has limited treatment options. The study s de...
August 26, 2024
BridgeBio Collaboration with CarDS Lab to Enhance Early Diagnosis of Transthyretin Amyloid Cardiomyopathy via Advanced Multimodal Artificial IntelligenceIn the distinguished arena of pharmaceutical sciences, a notable and progressive collaboration has emerged that promises to revolutionize the diagnostic approaches for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). BridgeBio, an eminent entity committed to the pursuit of developing transformative treatments for genetic diseases, has announced a consequential partnership with the Cardiovascular Data Science Laboratory (CarDS Lab), a venerated institution at the forefront of cardiovascular data analytics. This alliance is set to deploy a state-of-the-art mul...
August 19, 2024
Navigating Achondroplasia: BridgeBio Launches MyAchonJourney, a Vital Resource for Families PALO ALTO, Calif., Aug. 19, 2024 - In a significant move to support families and individuals affected by achondroplasia, BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics have announced the launch of the initial phase of MyAchonJourney, an innovative online resource dedicated to providing comprehensive information and guidance for those navigating life with this genetic condition.Achondroplasia is a common form of skeletal dysplasia resulting from a specific genetic mutation that impacts bone growth and development, leading to dwarfism. Afflicted individuals often face a range of physical chal...
April 7, 2024
:Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterized by the deposition of misfolded transthyretin protein in cardiac tissue, leading to heart failure. Acoramidis, a novel investigational therapy, has shown promise in mitigating disease progression. This article aims to present an extensive review of two articles highlighting the findings of a cardiac magnetic resonance (CMR) imaging substudy associated with the Phase 3 ATTRibute-CM study, evaluating the effects of acoramidis in ATTR-CM patients. ATTR-CM is a rare and devastating disease mainly affecting older individuals, particularly men, resulting in a poor quality of life and limited treatment options. The emerg...
February 2, 2024
In a groundbreaking development in the field of rare diseases, BridgeBio Pharma recently announced positive results from a single-arm Phase 3 study of Acoramidis in Japanese patients suffering from Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The study, conducted by BridgeBio s licensing partners, Alexion and AstraZeneca Rare Disease, showcased remarkable consistency with the global ATTRibute-CM Phase III trial. ATTR-CM is a degenerative disease caused by abnormal protein deposition in cardiac tissues. It is a life-threatening condition characterized by heart failure and is often associated with progressive heart damage. Despite being rare, ATTR-CM significantly impacts patients quality of life and has l...
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Bridgebio Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bridgebio Pharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
